Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR

Autor:	Laura Faivre, Frederic Rolland, Valérie Costes, François Bidault, Anne Auperin, Christian Borel, J. Delaye, B. Laguerre, S. Diffetocq, Caroline Even, L. Bozec Le Moal, Sylvie Zanetta, D. Cupissol, L. Digue, C. Le Tourneau, J. Fayette, Joël Guigay, Frederic Peyrade
Rok vydání:	2016
Předmět:	0301 basic medicine medicine.medical_specialty Pathology business.industry Hematology Gastroenterology Salivary gland carcinoma Pazopanib 03 medical and health sciences 030104 developmental biology Oncology Internal medicine Medicine Tumor growth In patient business medicine.drug
Zdroj:	Annals of Oncology. 27:vi340
ISSN:	0923-7534
DOI:	10.1093/annonc/mdw376.38
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c23d74bf3be6e0fcf8e2d08895fdd5a4 https://doi.org/10.1093/annonc/mdw376.38 Zobrazit plný text záznamu